The North Platte Telegraph The Alzheimer’s Association estimates that there are 37,000 Nebraskans age 65 or older with Alzheimer’s disease and other dementias. Nationwide 5.3 million people are living with the disease and a new individual is diagnosed every 70 seconds.
TUESDAY, Oct. 5 (HealthDay News) — Sophisticated brain imaging techniques may help doctors one day identify which patients with mild cognitive impairment are likely to progress to Alzheimer’s disease, Swiss researchers report.
The number of Alzheimer’s sufferers worldwide will double within 20 years to more than 65 million, according to a study published Tuesday to mark World Alzheimer’s Day.
Alzheimer’s Disease Researchers are talking up a promising new approach for people who suffer from Alzheimer’s or will be stricken with it someday. They’ve zeroed in on a protein called tau, which seems to signal how aggressive the mind-robbing disease will be. Researchers discovered that patients with mild Alzheimer’s and high levels of tau also harbored a genetic alteration that in turn …
If the findings of a tiny Philadelphia company hold up, doctors would for the first time have a reliable way to diagnose Alzheimers in patients with memory problems.
New research suggests that abnormalities in the process of blood clot formation may contribute to the pathogenesis of Alzheimer’s disease (AD). The study, published by Cell Press in the June 10 issue of the journal Neuron, advances our understanding of the link between vascular pathology and AD and proposes a new therapeutic strategy aimed at slowing cognitive decline.
A promising study from Rhode Island Hospital demonstrated that cholinesterase inhibitors (ChEI), a type of medication often prescribed for Alzheimer’s disease (AD), improved some cognitive skills in patients with mild AD - skills that are necessary for driving. Findings from the study showed that after being treated with a ChEI, AD patients improved in some computerized tests of executive …
( BMJ-British Medical Journal ) A special dementia care plan, involving regular assessments of patients with Alzheimer’s disease in specialist memory clinics, does not slow functional decline compared with usual care, finds a study published on bmj.com today.
WATERTOWN, Mass., May 11 /PRNewswire/ — EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase IIb study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with mild to moderate Alzheimer’s disease.
Buoyed by early results of stem cell-based trials on patients with Lou Gehrig’s disease, Eva Feldman, M.D., co-director of the A.
WEDNESDAY, April 14 (HealthDay News) — Involuntary crying or laughing can be a common symptom in patients with certain neurological disorders, such as Alzheimer’s, multiple sclerosis or amyotrophic lateral sclerosis (ALS).
By Bruce Japsen | Baxter International Inc.’s immune system drug helped preserve “thinking” abilities and reduced brain “shrinkage” in a small group of patients with Alzheimer’s disease that have been studied for 18 months, new research released this afternoon shows.
Washington, Mar 25 : Repetitive anaesthesia with isoflurane (one of the most common anaesthetics by inhalation) increases the risk of developing Alzheimer’s disease (AD) like symptoms in patients with genetic risk factors for the disease, according to a rodent study.
Researchers from Baylor College of Medicine in Houston, Texas studied 597 patients with Alzheimer’s disease in order to evaluate the reliability of the Alzheimer’s progression rate measure in predicting loss of cognition and function.
Pfizer Inc and Medivation, Inc announced results from two phase-3 trials of the investigational drug Dimebon (latrepirdine) in patients with Alzheimer’s disease (AD). In the Connection trial, Dimebon did not meet its co-primary or secondary efficacy endpoints compared to placebo.
The drug, called Dimebon, failed in its first late-stage clinical trial, dealing a blow to patients with Alzheimer’s and the companies developing the treatment, Medivation and Pfizer.
Amyloid-beta protein — the primary constituent of the plaques found in the brains of Alzheimer’s disease patients — may be part of the body’s first-line system to defend against infection. In a new study, researchers describe evidence that amyloid-beta protein is an antimicrobial peptide, part of the innate immune system.
Beta amyloid that builds up in the brains of patients with Alzheimer’s disease may go along with beneficial antimicrobial activity, researchers said.
March 3 (Bloomberg) — Beta amyloid that builds up in the brains of patients with Alzheimer’s disease may go along with beneficial antimicrobial activity, researchers said.
LOWELL, Mass., March 2 (UPI) — U.S.